Sponsored Links
News and Blogs
Total : 1 View more »
Amazon Biotech Announces Appointment of New CEO and New Corporate Counsel
www.biospace.com | May 21, 2008
NEW YORK, NY--(Marketwire - May 21, 2008) - Amazon Biotech, Inc. (OTCBB: AMZO) (FRANKFURT: B2DA) announced that Mr. Eliyahu BenTal Tolchinsky has been appointed as director and Chief Executive Officer of the Company. </p><p>Mr. Tolchinsky, a graduate of Cornell University and Tulane Law School, has
http://www.biospace.com/news_story.aspx?StoryID=97501&full=1
Web Sites
Total : 17 View more »
Amazon Biotech
Amazon Biotech, Inc. Retains ROI Group Associates, Inc. as Investor Re Amazon Biotech, Inc. Retains ROI Group Associates, Inc. as Investor Relations Counsel Company Launches Nationwide Investor Outreach Program as It Is About to Enter Clinical Trials NEW YORK, ...
Apria - resources - News
NEW YORK, NY, Oct 27, 2008 (MARKET WIRE via COMTEX) -- Amazon Biotech, Inc. (PINKSHEETS: AMZO) (FRANKFURT: B2DA) announced that Mr. Chaim J. Lieberman, the inventor and founder of Amazon Biotech Inc., was appointed as sole successor for management to Mr. Eliyahu Bental/Tolchinsky and Mr.
Pharmacy Choice - Pharmaceutical News - Amazon Biotech Inc. in Early Negotiations With Major
Amazon Biotech, Inc. (OTC BB: AMZB) (FRANKFURT: B2D) announced that it has secured the services of Mr. Stanley Fass to negotiate a joint venture agreement between Amazon Biotech and major pharmaceutical companies.
http://www.pharmacychoice.com/News/article.cfm?Article_ID=53367
Industry News Feeds : Press Room : Micromedex
Get the news that matters to you. Create your own customized news service that delivers the latest information directly to you. Plus you can view the most current press releases from Micromedex.
http://www.micromedex.com/pressroom/news_feeds/?story_ID=93426&category=16
News from Zibb.com
Total : 2 View more »
Amazon Biotech Announces Appointment of Chaim J. Lieberman, the Inventor and Founder, as New
NEW YORK, NY, Oct 27, 2008 (MARKET WIRE via COMTEX) --
Amazon Biotech, Inc. (PINKSHEETS: AMZO) (FRANKFURT: B2DA) announced that Mr. Chaim J. Lieberman, the inventor and founder of Amazon Biotech Inc., was appointed as sole successor for management to Mr. Eliyahu Bental/Tolchinsky and Mr. Bental resigned.
Mr. Lieberman is quoted as saying,"I look forward to investing good energy to focus the company on its pharmaceutical vision and goals."
Amazon Biotech, Inc. is a natural plant pharmaceutical drug company, primarily developing immune modulator drugs. AMZ0026 is the Company's first such drug approved for Phase 2 HIV/Aids human trials by the FDA. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.
Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com/.
Forward-Looking Statements
"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof. Commitment to do a study does not represent that the Company has FDA approval on the protocol to start the study.
For more information contact www.amazonbiotech.com cj@amazonbiotech.com IR Contact: LC Group Rick Lutz 404-261-1196 lcgroup@mindspring.com
SOURCE: Amazon Biotech, Inc.
http://www.amazonbiotech.com mailto:cj@amazonbiotech.com mailto:lcgroup@mindspring.com
Tags: aids appointment biotechnology drugs energy fda frankfurt hiv market pharmaceuticals products sales securities
Companies: Amazon Biotech Inc (AMZO)
Amazon Biotech Announces Filing of 14A to Set Shareholder Meeting - Zibb.com
NEW YORK, NY, Sep 26, 2008 (MARKET WIRE via COMTEX) --
Amazon Biotech, Inc. (PINKSHEETS: AMZO) (FRANKFURT: B2DA) announced that a preliminary 14A was filed by Amazon to set a shareholder meeting, at a time to be announced, to elect a three member Board of Directors and to address such other matters as may properly come before the meeting or any adjournments thereof.
Amazon Biotech, Inc. is a natural plant pharmaceutical drug company, primarily developing immunomodulator drugs. AMZ0026 is the Company's first such drug to be used for the treatment of HIV/AIDS. The Company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future with the goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials or enter the FDA Fast Track program to reach the marketplace. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.
Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com/.
Forward-Looking Statements
"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof. Commitment to do a study does not represent that the Company has FDA approval on the protocol to start the study.
Contact: LC Group Rick Lutz 404-261-1196 lcgroup@mindspring.com
SOURCE: Amazon Biotech, Inc.
mailto:lcgroup@mindspring.com
Tags: aids biotechnology clinical drugs fda frankfurt hiv joint venture market pharmaceuticals products sales securities track
Companies: Amazon Biotech Inc (AMZO)
News from Zibb.com
Explore Related Products
Explore in Related Industries
- Amazon Biotech Incorporated in:
- Chemicals, Plastics & Rubber (5)
